Compare · NVO vs RNAZ
NVO vs RNAZ
Side-by-side comparison of Novo Nordisk A/S (NVO) and TransCode Therapeutics Inc. (RNAZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNAZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 37865.0x RNAZ ($4.8M).
- Over the past year, NVO is down 45.7% and RNAZ is down 35.4% - RNAZ leads by 10.3 points.
- RNAZ has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for RNAZ).
- Company
- Novo Nordisk A/S
- TransCode Therapeutics Inc.
- Price
- $41.01-4.51%
- $4.68-17.61%
- Market cap
- $183.15B
- $4.8M
- 1M return
- -10.44%
- -38.26%
- 1Y return
- -45.66%
- -35.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RNAZ
- TransCode Therapeutics to Host R&D Webcast on June 18, 2026
- TransCode Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
- SEC Form DEF 14A filed by TransCode Therapeutics Inc.
- TransCode Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations
- TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
- SEC Form DEFA14A filed by TransCode Therapeutics Inc.
- Amendment: TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form EFFECT filed by TransCode Therapeutics Inc.